Similarly, another HSV-1–based agent in clinical development, RP1, was well tolerated and resulted in durable responses in combination with systemic immunotherapy (the programmed cell death protein 1 monoclonal antibody nivolumab) in patients with melanoma and non-melanoma skin cancers (Milhem et al., 2022). The gene discussed is PDCD1; the disease is melanoma.